Home Healthcare Biotechnology Companion Diagnostics for Oncology Market

Companion Diagnostics for Oncology Market Size, Share & Trends Analysis Report By Products and Services (Assays, Kits, and Reagents, Software and Services), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS)), By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma, Others), By End-User (Pharmaceutical and Biopharmaceutical Companies, Laboratories, Contract Research Organizations, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Companion Diagnostics for Oncology Market, By Products and Services 2022-2034 (USD MILLION/ Units)
    1. Assays, Kits, and Reagents
    2. Software and Services
  2. Companion Diagnostics for Oncology Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. Polymerase Chain Reaction (PCR)
    2. Next-Generation Sequencing (NGS)
  3. Companion Diagnostics for Oncology Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Breast Cancer
    2. Lung Cancer
    3. Colorectal Cancer
    4. Gastric Cancer
    5. Melanoma
    6. Others
  4. Companion Diagnostics for Oncology Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Pharmaceutical and Biopharmaceutical Companies
    2. Laboratories
    3. Contract Research Organizations
    4. Others
  5. Regional Companion Diagnostics for Oncology Market
    1. North America
      1. North America Companion Diagnostics for Oncology Market By Products and Services 2022-2034 (USD MILLION/ Units)
        1. Assays, Kits, and Reagents
        2. Software and Services
      2. North America Companion Diagnostics for Oncology Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR)
        2. Next-Generation Sequencing (NGS)
      3. North America Companion Diagnostics for Oncology Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Breast Cancer
        2. Lung Cancer
        3. Colorectal Cancer
        4. Gastric Cancer
        5. Melanoma
        6. Others
      4. North America Companion Diagnostics for Oncology Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Laboratories
        3. Contract Research Organizations
        4. Others
      5. U.S.
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      6. Canada
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
    2. Europe
      1. Europe Companion Diagnostics for Oncology Market By Products and Services 2022-2034 (USD MILLION/ Units)
        1. Assays, Kits, and Reagents
        2. Software and Services
      2. Europe Companion Diagnostics for Oncology Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR)
        2. Next-Generation Sequencing (NGS)
      3. Europe Companion Diagnostics for Oncology Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Breast Cancer
        2. Lung Cancer
        3. Colorectal Cancer
        4. Gastric Cancer
        5. Melanoma
        6. Others
      4. Europe Companion Diagnostics for Oncology Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Laboratories
        3. Contract Research Organizations
        4. Others
      5. U.K.
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      6. Germany
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      7. France
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      8. Spain
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      9. Italy
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      10. Russia
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      11. Nordic
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      12. Benelux
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      13. Rest of Europe
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
    3. APAC
      1. APAC Companion Diagnostics for Oncology Market By Products and Services 2022-2034 (USD MILLION/ Units)
        1. Assays, Kits, and Reagents
        2. Software and Services
      2. APAC Companion Diagnostics for Oncology Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR)
        2. Next-Generation Sequencing (NGS)
      3. APAC Companion Diagnostics for Oncology Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Breast Cancer
        2. Lung Cancer
        3. Colorectal Cancer
        4. Gastric Cancer
        5. Melanoma
        6. Others
      4. APAC Companion Diagnostics for Oncology Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Laboratories
        3. Contract Research Organizations
        4. Others
      5. China
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      6. Korea
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      7. Japan
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      8. India
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      9. Australia
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      10. Taiwan
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      11. South East Asia
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      12. Rest of Asia-Pacific
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
    4. Middle East and Africa
      1. Middle East and Africa Companion Diagnostics for Oncology Market By Products and Services 2022-2034 (USD MILLION/ Units)
        1. Assays, Kits, and Reagents
        2. Software and Services
      2. Middle East and Africa Companion Diagnostics for Oncology Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR)
        2. Next-Generation Sequencing (NGS)
      3. Middle East and Africa Companion Diagnostics for Oncology Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Breast Cancer
        2. Lung Cancer
        3. Colorectal Cancer
        4. Gastric Cancer
        5. Melanoma
        6. Others
      4. Middle East and Africa Companion Diagnostics for Oncology Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Laboratories
        3. Contract Research Organizations
        4. Others
      5. UAE
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      6. Turkey
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      7. Saudi Arabia
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      8. South Africa
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      9. Egypt
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      10. Nigeria
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      11. Rest of MEA
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
    5. LATAM
      1. LATAM Companion Diagnostics for Oncology Market By Products and Services 2022-2034 (USD MILLION/ Units)
        1. Assays, Kits, and Reagents
        2. Software and Services
      2. LATAM Companion Diagnostics for Oncology Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR)
        2. Next-Generation Sequencing (NGS)
      3. LATAM Companion Diagnostics for Oncology Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Breast Cancer
        2. Lung Cancer
        3. Colorectal Cancer
        4. Gastric Cancer
        5. Melanoma
        6. Others
      4. LATAM Companion Diagnostics for Oncology Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Laboratories
        3. Contract Research Organizations
        4. Others
      5. Brazil
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      6. Mexico
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      7. Argentina
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      8. Chile
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      9. Colombia
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
      10. Rest of LATAM
        1. Assays, Kits, and Reagents
        2. Software and Services
        3. Polymerase Chain Reaction (PCR)
        4. Next-Generation Sequencing (NGS)
        5. Breast Cancer
        6. Lung Cancer
        7. Colorectal Cancer
        8. Gastric Cancer
        9. Melanoma
        10. Others
        11. Pharmaceutical and Biopharmaceutical Companies
        12. Laboratories
        13. Contract Research Organizations
        14. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.